Baseline values and percentage of recovery of left ventricular developed pressure, heart rate, coronary flow and final left ventricular end-diastolic pressure value in study 3
| . | Control . | 5HD . | Esax . | Esax + 5HD . | P-value . |
|---|---|---|---|---|---|
| HR | |||||
| Baseline (beats/min) | 308.2±18.1 | 299.8±18.7 | 308.3±20.5 | 309.9±14.2 | 0.358 |
| Recovery (%) | 85.6±9.4 | 88.1±6.1 | 85.1±10.5 | 86.3±8.6 | 0.936 |
| LVDP | |||||
| Baseline (mmHg) | 151.7±4.4 | 145.7±10.1 | 151.0±6.0 | 156.7±7.6 | 0.114 |
| LVEDP | |||||
| Baseline (mmHg) | 5.7±0.6 | 5.8±1.1 | 4.8±1.0 | 4.9±0.7 | 0.133 |
| Final (mmHg) | 70.0±5.7 | 70.7±10.2 | 58.4±9.2 | 59.0±11.7 | 0.055 |
| CF | |||||
| Baseline (ml/min) | 19.6±2.6 | 18.5±3.2 | 17.8±±1.9 | 17.7±2.0 | 0.592 |
| Recovery (%) | 51.7±10.0 | 46.0±13.3 | 60.4±9.4 | 51.1±8.9 | 0.212 |
| . | Control . | 5HD . | Esax . | Esax + 5HD . | P-value . |
|---|---|---|---|---|---|
| HR | |||||
| Baseline (beats/min) | 308.2±18.1 | 299.8±18.7 | 308.3±20.5 | 309.9±14.2 | 0.358 |
| Recovery (%) | 85.6±9.4 | 88.1±6.1 | 85.1±10.5 | 86.3±8.6 | 0.936 |
| LVDP | |||||
| Baseline (mmHg) | 151.7±4.4 | 145.7±10.1 | 151.0±6.0 | 156.7±7.6 | 0.114 |
| LVEDP | |||||
| Baseline (mmHg) | 5.7±0.6 | 5.8±1.1 | 4.8±1.0 | 4.9±0.7 | 0.133 |
| Final (mmHg) | 70.0±5.7 | 70.7±10.2 | 58.4±9.2 | 59.0±11.7 | 0.055 |
| CF | |||||
| Baseline (ml/min) | 19.6±2.6 | 18.5±3.2 | 17.8±±1.9 | 17.7±2.0 | 0.592 |
| Recovery (%) | 51.7±10.0 | 46.0±13.3 | 60.4±9.4 | 51.1±8.9 | 0.212 |
Data are presented as means ± standard deviation.
CF: coronary flow; control: not treated; Esax: esaxerenone (0.1 μmol/l) infused for 10 min before ischaemia; Esax + 5HD: esaxerenone (0.1 μmol/l) with 5-hydroxydecanoate (50 μmol/l) infused for 10 min before ischaemia; 5HD: 5-hydroxydecanoate (50 μmol/l) infused for 10 min before ischaemia; HR: heart rate; LVDP: left ventricular developed pressure; LVEDP: left ventricular end-diastolic pressure.
Baseline values and percentage of recovery of left ventricular developed pressure, heart rate, coronary flow and final left ventricular end-diastolic pressure value in study 3
| . | Control . | 5HD . | Esax . | Esax + 5HD . | P-value . |
|---|---|---|---|---|---|
| HR | |||||
| Baseline (beats/min) | 308.2±18.1 | 299.8±18.7 | 308.3±20.5 | 309.9±14.2 | 0.358 |
| Recovery (%) | 85.6±9.4 | 88.1±6.1 | 85.1±10.5 | 86.3±8.6 | 0.936 |
| LVDP | |||||
| Baseline (mmHg) | 151.7±4.4 | 145.7±10.1 | 151.0±6.0 | 156.7±7.6 | 0.114 |
| LVEDP | |||||
| Baseline (mmHg) | 5.7±0.6 | 5.8±1.1 | 4.8±1.0 | 4.9±0.7 | 0.133 |
| Final (mmHg) | 70.0±5.7 | 70.7±10.2 | 58.4±9.2 | 59.0±11.7 | 0.055 |
| CF | |||||
| Baseline (ml/min) | 19.6±2.6 | 18.5±3.2 | 17.8±±1.9 | 17.7±2.0 | 0.592 |
| Recovery (%) | 51.7±10.0 | 46.0±13.3 | 60.4±9.4 | 51.1±8.9 | 0.212 |
| . | Control . | 5HD . | Esax . | Esax + 5HD . | P-value . |
|---|---|---|---|---|---|
| HR | |||||
| Baseline (beats/min) | 308.2±18.1 | 299.8±18.7 | 308.3±20.5 | 309.9±14.2 | 0.358 |
| Recovery (%) | 85.6±9.4 | 88.1±6.1 | 85.1±10.5 | 86.3±8.6 | 0.936 |
| LVDP | |||||
| Baseline (mmHg) | 151.7±4.4 | 145.7±10.1 | 151.0±6.0 | 156.7±7.6 | 0.114 |
| LVEDP | |||||
| Baseline (mmHg) | 5.7±0.6 | 5.8±1.1 | 4.8±1.0 | 4.9±0.7 | 0.133 |
| Final (mmHg) | 70.0±5.7 | 70.7±10.2 | 58.4±9.2 | 59.0±11.7 | 0.055 |
| CF | |||||
| Baseline (ml/min) | 19.6±2.6 | 18.5±3.2 | 17.8±±1.9 | 17.7±2.0 | 0.592 |
| Recovery (%) | 51.7±10.0 | 46.0±13.3 | 60.4±9.4 | 51.1±8.9 | 0.212 |
Data are presented as means ± standard deviation.
CF: coronary flow; control: not treated; Esax: esaxerenone (0.1 μmol/l) infused for 10 min before ischaemia; Esax + 5HD: esaxerenone (0.1 μmol/l) with 5-hydroxydecanoate (50 μmol/l) infused for 10 min before ischaemia; 5HD: 5-hydroxydecanoate (50 μmol/l) infused for 10 min before ischaemia; HR: heart rate; LVDP: left ventricular developed pressure; LVEDP: left ventricular end-diastolic pressure.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
